Entrepreneur Success Story

News Archive

Siolta Therapeutics wins the Bugs, Drugs, & Beyond QuickFire Challenge

  Johnson & Johnson Innovation, JLABS and the Janssen Human Microbiome Institute (JHMI) launched the second Bugs, Drugs, & Beyond QuickFire Challenge. Taking place in both San Francisco and Cambridge, the Challenge awarded winners with a customized package of support from the JHMI and JLABS, including coaching and $75,000 in funding or entrance to the South San Francisco or Boston JLABS sites, […]

Read more

Indee Labs closed a $1.3M angel round

  Indee Labs closed a $1.3M angel round Indee Labs recently closed a $1.3M angel round and demonstrated functional modification of human primary T-cells with high efficiency (30 to 60%), cell viability (>85%) and recovery (>90%) without T-cell exhaustion or activation. The team also signed its first customer — a clinical-stage biotechnology company developing gene-modified B-cell therapies for rare disease […]

Read more

OneSkin closes $2M Financing to reverse aging skin

  OneSkin closes $2M Financing to reverse aging skin OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.

Read more

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne Led by dermatologist Dr. Emma Taylor, the Naked Biome team is developing microbiome-based acne therapeutics. They have now closed a $5 million seed round to get them through clinical proof-of-principle.

Read more

Celgene acquires Delinia

Celgene acquires Delinia Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!  

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more

Nucleo Life Sciences

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.

Read more

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter